Earnings summaries and quarterly performance for BridgeBio Pharma.
Executive leadership at BridgeBio Pharma.
Board of directors at BridgeBio Pharma.
AS
Ali Satvat
Detailed
Director
AE
Andrea Ellis
Detailed
Director
AL
Andrew Lo
Detailed
Director
CH
Charles Homcy
Detailed
Lead Director
DD
Douglas Dachille
Detailed
Director
EA
Eric Aguiar
Detailed
Director
FM
Frank McCormick
Detailed
Director
FH
Fred Hassan
Detailed
Lead Independent Director
HV
Hannah Valantine
Detailed
Director
JM
James Momtazee
Detailed
Director
JC
Jennifer Cook
Detailed
Director
RS
Randal Scott
Detailed
Director
RD
Ronald Daniels
Detailed
Director
Research analysts who have asked questions during BridgeBio Pharma earnings calls.
Biren Amin
Piper Sandler Companies
6 questions for BBIO
Also covers: ALLO, APLS, CMPX +5 more
TV
Tyler Van Buren
TD Cowen
6 questions for BBIO
Also covers: ADVM, ALLO, ARGX +13 more
Andrew Tsai
Jefferies
5 questions for BBIO
Also covers: ARQT, ATAI, ATHA +16 more
AR
Anupam Rama
JPMorgan Chase & Co.
4 questions for BBIO
Also covers: APLS, BOLD, CTMX +18 more
Cory Kasimov
Evercore ISI
4 questions for BBIO
Also covers: ALNY, BMRN, BNTX +7 more
MF
Mani Foroohar
Leerink Partners
4 questions for BBIO
Also covers: ADVM, ALNY, ARWR +9 more
PC
Paul Choi
Goldman Sachs
4 questions for BBIO
Also covers: AMRN, ARVN, ASND +13 more
SS
Salim Syed
Mizuho Securities
4 questions for BBIO
Also covers: AUTL, CYTK, INCY +6 more
EM
Eliana Merle
UBS
3 questions for BBIO
Also covers: ALNY, APLS, ARVN +17 more
Jason Zemansky
Bank of America
3 questions for BBIO
Also covers: ABOS, CYTK, ESPR +5 more
AJ
Adi Jayaraman
Evercore ISI
2 questions for BBIO
DB
Danielle Brill
Truist Securities
2 questions for BBIO
Also covers: ACAD, ARGX, BIIB +6 more
GH
Greg Harrison
RBC Capital Markets
2 questions for BBIO
Also covers: ADCT, APLS, EDIT +3 more
JS
Josh Schimmer
Cantor Fitzgerald
2 questions for BBIO
Also covers: BYSI, CRNX, KRYS +5 more
Ryan Mcelroy
Leerink Partners
2 questions for BBIO
Also covers: MIRM, RGNX
TA
Trevor Allred
Oppenheimer & Co. Inc.
2 questions for BBIO
Also covers: CASI, LGND, VRDN
B
Bennett
Mizuho
1 question for BBIO
TT
Thomas Trimarchi
Raymond James
1 question for BBIO
Recent press releases and 8-K filings for BBIO.
BridgeBio Pharma Reports Strong Q4 and Full-Year 2025 Revenues, Highlights Positive Phase 3 Results and Future Cash Generation
BBIO
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- BridgeBio Pharma reported total revenues of $154.2 million in Q4 2025 and $502.1 million for the full year 2025, primarily driven by Attruby net product revenue of $146 million in Q4.
- The company announced positive top-line Phase 3 results for encaleret in ADH1, BBP-418 in LGMD2I, and infigratinib in achondroplasia, marking a transformative inflection point.
- BridgeBio anticipates its pipeline will transition from a cash-consumptive business to a cash-generating one by late 2027, projecting over $600 million in profit from its four post-Phase 3 assets by 2028.
- The company ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities, and issued $632.5 million in convertible notes in January 2026, providing significant cash runway.
- Three programs, BBP-418, infigratinib, and the Canavan gene therapy program, have received Rare Pediatric Disease Designation, making them eligible for Priority Review Vouchers upon approval.
3 days ago
BridgeBio Pharma Reports Strong Q4 2025 Results and Positive Late-Stage Pipeline Data
BBIO
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- BridgeBio Pharma reported total revenues of $154.2 million in Q4 2025 and $502.1 million for the full year 2025, primarily driven by Attruby net product revenue of $146 million in Q4 and $362.4 million for the full year. The company's cash burn for 2025 was $446 million net of revenue.
- The company announced positive top-line Phase 3 results for encaleret in ADH1, BBP-418 in LGMD2I, and infigratinib in achondroplasia, marking a transformative inflection point for the company.
- The Phase 3 study for infigratinib in achondroplasia successfully met its primary endpoint, demonstrating a mean treatment difference against placebo of 2.1 centimeters per year in average height velocity at week 52 (p-value < 0.0001).
- BridgeBio anticipates transitioning from a cash-consumptive business to a significant cash generator, expecting to generate over $600 million in profit by 2028 from its four post-Phase 3 assets. The company also expects to receive Priority Review Vouchers for BBP-418, infigratinib, and its Canavan gene therapy program upon approval.
3 days ago
BridgeBio Pharma Reports Strong Q4 and Full-Year 2025 Revenues, Highlights Positive Phase III Results and Attruby Momentum
BBIO
Earnings
Revenue Acceleration/Inflection
Product Launch
- BridgeBio Pharma reported total revenues of $154.2 million for Q4 2025 and $502.1 million for the full year 2025, with Attruby net product revenue reaching $146 million in Q4 and $362.4 million for the full year.
- The company announced positive top-line Phase III results for encaleret in ADH1, BBP-418 in LGMD2I, and infigratinib in achondroplasia, with infigratinib demonstrating a mean treatment difference of 2.1 cm per year and a p-value of less than 0.0001.
- Attruby continued its strong commercial momentum, achieving 35% quarter-over-quarter growth in net product revenue in Q4 2025 and 7,804 unique patient prescriptions as of February 20th, 2026.
- BridgeBio ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities, and issued $632.5 million in convertible notes in January 2026 to support its transition into a multi-product business.
- The company anticipates the launch of encaleret and BBP-418 in late 2026 or early 2027, with cash burn expected to hold steady through most of 2026 before decreasing towards year-end due to Attruby's expanding operating margin.
3 days ago
BridgeBio Pharma Reports Q4 and Full Year 2025 Financial Results and Pipeline Progress
BBIO
Earnings
Product Launch
Debt Issuance
- BridgeBio Pharma reported total revenues, net, of $154.2 million for Q4 2025 and $502.1 million for the full year 2025, primarily from net product revenue of $146.0 million and $362.4 million, respectively. The company recorded a net loss attributable to common stockholders of $192.9 million for Q4 2025 and $724.9 million for FY 2025.
- As of December 31, 2025, BridgeBio held $587.5 million in cash, cash equivalents, and marketable securities and subsequently completed the issuance of $632.5 million in 2033 convertible notes in January 2026 to support operations.
- Attruby (acoramidis) demonstrated strong commercial performance with 7,804 unique patient prescriptions by February 20, 2026, and achieved 35% quarter-over-quarter growth in net product revenue in Q4 2025.
- The company announced three positive Phase 3 trial readouts (for infigratinib, BBP-418, and encaleret) and plans for NDA submissions in 1H 2026 for BBP-418 and encaleret, with anticipated U.S. launches in late 2026/early 2027.
3 days ago
BridgeBio Pharma Reports Q4 and Full Year 2025 Financial Results
BBIO
Earnings
Debt Issuance
Product Launch
- BridgeBio Pharma reported $154.2 million in total net revenues for the fourth quarter of 2025 and $502.1 million for the full year 2025, primarily from $146.0 million in Q4 net product revenue from Attruby.
- The company ended December 31, 2025, with $587.5 million in cash, cash equivalents, and marketable securities, and completed a $632.5 million aggregate principal amount convertible notes issuance in January 2026.
- BridgeBio announced three positive Phase 3 trial readouts for infigratinib (PROPEL 3), BBP-418 (FORTIFY), and encaleret (CALIBRATE).
- Following these positive results, the company plans NDA submissions in 1H 2026 for BBP-418 and encaleret, with anticipated U.S. launches in late 2026/early 2027, and an NDA submission for infigratinib in 2H 2026.
- For the fourth quarter and full year ended December 31, 2025, the company recorded a net loss attributable to common stockholders of $192.9 million and $724.9 million, respectively.
3 days ago
BridgeBio Pharma, Inc. Reports Positive Phase 3 Topline Results for Oral Infigratinib in Achondroplasia
BBIO
Product Launch
New Projects/Investments
Guidance Update
- BridgeBio Pharma, Inc. announced positive topline results from the PROPEL 3 global Phase 3 pivotal study of oral infigratinib in children with achondroplasia on February 12, 2026.
- The study successfully met its primary endpoint, showing a mean treatment difference of +2.10 cm/year in annualized height velocity against placebo at Week 52.
- Oral infigratinib achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, with an LS mean treatment difference of -0.05 (p<0.05) in children younger than 8 years old.
- The drug was well tolerated, with no discontinuations or serious adverse events related to the study drug.
- BridgeBio plans to submit New Drug Application (NDA) and Marketing Authorization Application (MAA) in the second half of 2026 for achondroplasia and will accelerate development for hypochondroplasia.
Feb 12, 2026, 9:05 PM
BridgeBio Reports Positive Phase 3 Results for Infigratinib
BBIO
Product Launch
New Projects/Investments
- BridgeBio's oral FGFR3 inhibitor infigratinib met the primary endpoint in the Phase 3 PROPEL 3 trial for children with achondroplasia, demonstrating an average treatment difference versus placebo of approximately +2.10 cm/year in annualized height velocity at one year.
- The trial also showed the first statistically significant improvement in upper-to-lower body proportionality in a randomized achondroplasia trial, particularly in children younger than eight.
- Infigratinib was generally well tolerated, with no drug-related serious adverse events or discontinuations reported.
- BridgeBio plans to pursue regulatory discussions and aims to file a New Drug Application and Marketing Authorization Application in the U.S. and Europe in the second half of 2026.
- Following the positive topline data, BridgeBio shares experienced intraday gains between roughly 5% and 15%.
Feb 12, 2026, 1:33 PM
BridgeBio Pharma Announces Positive PROPEL 3 Phase 3 Topline Results for Infigratinib in Achondroplasia
BBIO
Product Launch
New Projects/Investments
- BridgeBio Pharma announced positive topline results from the PROPEL 3 Phase 3 study of oral infigratinib for children with achondroplasia.
- The study demonstrated best-in-class efficacy with significant improvements in AHV, height-z score, and proportionality, and the drug was well-tolerated with no serious adverse events related to the study drug.
- The company plans to submit New Drug Applications (NDA) to the FDA and Marketing Authorization Applications (MAA) to the EMA in the second half of 2026.
Feb 12, 2026, 1:00 PM
BridgeBio Pharma Announces Positive Phase III Results for Infigratinib in Achondroplasia
BBIO
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- BridgeBio Pharma announced positive Phase III results from its PROPEL-3 clinical trial for infigratinib in achondroplasia, demonstrating significant improvements across key efficacy measures.
- Infigratinib met its primary endpoint, showing a mean difference of +2.1 centimeters per year and an LS mean difference of +1.74 centimeters per year in annualized height velocity compared to placebo, both with p-values less than 0.0001.
- The trial also reported statistically significant improvements in height Z-score (LS mean difference of +0.32 standard deviations against placebo, p < 0.0001) and, for the first time, in upper-to-lower body proportionality in children aged 3 to 8 years (LS mean difference of -0.05 against placebo, p < 0.05).
- Infigratinib was well-tolerated, with no safety concerns, no Grade 3 or higher adverse events, no SAEs related to the study drug, and no discontinuations related to the study drug.
- BridgeBio plans to launch infigratinib, anticipating it will be the first and only oral therapeutic option for achondroplasia, with the global skeletal dysplasia market (including achondroplasia) estimated at $5 billion.
Feb 12, 2026, 1:00 PM
BridgeBio Pharma Announces Positive Phase 3 Results for Infigratinib in Achondroplasia
BBIO
Product Launch
New Projects/Investments
- BridgeBio Pharma announced positive Phase 3 results from its PROPEL-3 clinical trial for infigratinib in children with achondroplasia.
- The trial met its primary endpoint, demonstrating a mean difference of +2.1 centimeters per year in annualized height velocity (AHV) against placebo, and an LS mean difference of +1.74 centimeters per year (p < 0.0001).
- Infigratinib also showed significant improvements in key secondary endpoints, including an LS mean change of +0.32 standard deviation score in height Z-score and a statistically significant improvement in body proportions in children aged 3 to 8 years.
- The drug exhibited a well-tolerated safety profile with no serious adverse events related to the study drug and no adverse events associated with FGFR1 or FGFR2 inhibition, offering an oral therapeutic option.
- BridgeBio plans to submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Application (MAA) for the EMA in the second half of 2026, targeting a skeletal dysplasia market estimated at $5 billion.
Feb 12, 2026, 1:00 PM
Quarterly earnings call transcripts for BridgeBio Pharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more